A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone
NCT04158947
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
130
Enrollment
OTHER
Sponsor class
Conditions
HER2-positive Breast Cancer
Brain Metastases
Interventions
DRUG:
Afatinib
DRUG:
T-DM1
Sponsor
xuexin he